87 ADHD patients were ERP-tested twice; test 2 on stimulant medication; followed by 4 weeks clinical trial. After the trial they were classified as responders (REs) or non-responders (non-REs). REs and non-REs differed significantly in their single-dose responses on the P3no-go (d = 1.76), suggesting utility of P3no-go ERP in predicting treatment response.
Introduction
Attention-deficit hyperactivity disorder (ADHD) is a common developmental disorder involving problems with attention and/or hyperactivity and impulsivity. It is typically identified in childhood, with symptoms often persisting throughout adulthood (Faraone et al., 2000) . Comorbid disorders in behavior, emotion, learning, and autism spectrum are common (Hermens et al., 2006; American Psychiatric Association, 2013) . Prevalence of ADHD is approximately 3-7% in school-aged children (Willcutt, 2012; Paule et al., 2000) and is relatively consistent across class, culture, and ethnic background (Polanczyk and Jensen, 2008; Barkley, 2006) . The influence of genetic factors is well documented (Barkley, 2006; Nigg, 2005) .
Medical treatments with psychostimulants like methylphenidate (MPH), dextroamphetamine (DEX) atomoxetine (ATX) are widely used. Therapeutic effects of stimulants (reduced restlessness/hyperactivity, improved sustained attention, reduction of impulsive acts), are reported in approximately 70% of patients (Greenhill et al., 2002; Hodgkins et al., 2012; Parr et al., 2003; Pliszka, 2003; Spencer et al., 1996; Ishii-Takahashi et al., 2015; Cho et al., 2007) . A shift to DEX or ATX for non-responders (non-REs) increases therapeutic effects to 80% (Barkley, 2006) . Numerous studies have implicated the fronto-subcortical networks of the brain as a prime candidate for the source of the underlying dysfunction; including hypofunctioning dopamine and noradrenalin systems (Hermens et al., 2005) . Psychostimulants seem to increase activation in the frontal cortex and striatum (Volkow et al., 2012; Engert and Pruessner, 2008 )-key areas of cognitive control-and may underlie the positive clinical effects of stimulants (Rubia et al., 2014) .
Early identification of non-REs is critical in order to avoid long-term-ineffective medication trials and to ensure that other treatment options (medical and/or psycho-social) are initiated. The traditional approach has been to attempt to identify predictors based on information collected before initiation of medication trials. Despite these attempts, there is currently no reliable method for predicting how patients will respond, without exposure to a trial period of medication (Johnston et al., 2015) . As effects of MPH and DEX can often be observed on single doses, however, another less frequent approach to predicting clinical response is to examine effects of a single dose.
Predictors of stimulant medication response
Previous studies aimed at predicting treatment response to medication have applied neuropsychological test results, EEG data, demographic and behavioral parameters (gender, age, SES, diagnoses, scores on rating scales), or a combination of these variables (Barkley, 1976; Gray and Kagan, 2000; Chabot et al., 1999; Barkley et al., 1991; Hale et al., 2011; Tannock et al., 1995) . The predictive power of neuropsychological tests is considered modest (Fernandez-Jaen et al., 2008; Nichols and Waschbusch, 2004; Riccio et al., 2001; Coghill et al., 2007; Ogrim et al., 2014) .
EEG-based measures have been used as predictors of response to stimulants. A 2005 review (Hermens et al., 2005) identified a combination of behavioral and electrophysiological parameters as the most promising approach. Several cognitive ERP components, such as the P3 component following cues (cueP3), targets (P3go/ P3b), no-go signals (P3no-go), contingent negative variation (CNV), and N2no-go are frequently found to differ between ADHD subjects and healthy controls (Sangal and Sangal, 2006; Johnstone et al., 2013; Brandeis et al., 2002) . Some of these components, particularly the P3b, have been investigated as predictors of stimulant medication response (Chabot et al., 1999; Sangal and Sangal, 2004) . The P3b component has a parietal distribution, however, and most functional imaging studies indicate MPH effects primarily in frontal regions (Rubia et al., 2014) . Investigating the predictive power of more anteriorly distributed components such as CNV, N2no-go, and P3no-go could therefore prove particularly fruitful. We previously found that whereas non-REs showed deviations in the parietally distributed cue-P3 compared with healthy controls, medication responders deviated in the more frontally distributed P3no-go and CNV components (Ogrim et al., 2014) .
We are aware of only one study (Young et al., 1995) examining changes in ERP components induced by a single dose of MPH as a basis for predicting clinical response to stimulants in children with ADHD. The children whose P3b amplitude from an auditory oddball paradigm increased by >30% on a single dose were classified as REs six months later with an accuracy of 81%. That study was based on a relatively small group (N = 35), with about an equal number of REs and non-REs. Our study examines changes caused by a single dose of stimulant medication in a larger group of ADHD subjects and includes behavioral variables and more frontally distributed ERP components.
Considerations in predicting medication response
There are many obstacles in identifying powerful predictors of medication response. First, one must consider inclusion and exclusion criteria. Most ADHD patients have comorbid disorders, and studies aimed at finding predictors of clinical use should include all ADHD patients. The proportion of REs vs. non-REs should be proximal to the reported prevalence in population studies (about 70-80% REs), as changes in base rate will affect the accuracy of the predictive model. Second, there is still no consensus regarding how best to operationalize the criterion variable of treatment response. Behavior ratings from parents and teachers are frequently used as outcome measures, but are criticized for being vulnerable to placebo and source effects (Ogrim et al., 2014; Herrerias et al., 2001) . Gathering information from several sources and using both standardized and unstructured methods can counteract some of these problems while also maintaining the desired ecological validity when evaluating the participants' day-to-day functioning prior to and during stimulant medication try-out.
Third, one must consider the number of predictor variables to include in a model. Previous studies indicate the necessity of more than one (Hermens et al., 2005) , yet there should be as few predictors as possible. Increasing the number of predictors increases the risk of model overfitting, thereby limiting generalizability. Some studies have suggested that the number of predictor variables in the model should be less than 1 per 10 subjects having the least common outcome (Peduzzi et al., 1996) , although simulation studies indicate that this criterion may be somewhat strict (Vittinghoff and McCulloch, 2007) . Collection of predictor data should also not be overly demanding of resources or time for patients and their families.
Finally, it should be considered that the base rate of REs relative to non-REs in the ADHD population (approximately 70% and 30%, respectively) itself provides a predictive model with 70% accuracy, which correctly classifies all REs and misses all non-REs. Curiously, this aspect is not always considered in the published literature. To be useful, a predictive model must have significantly higher accuracy than the base rate model and provide a means of detecting non-REs who will be in need of other types of treatment.
Study aims and hypotheses
We investigated whether effects of a single dose of stimulant medication in 87 ADHD patients (27 girls; 73 medication-naïve) aged 8-18 years could predict clinical medication response after a four-week medication trial. The study included four behavioral variables (reaction time [RT] , RT variability [RTvar] , omission errors, commission errors) and five ERP component amplitudes (cue-P3, CNV, P3go, N2no-go, P3no-go) that have been found to differ between ADHD subjects and healthy controls. By investigating the predictive power of single-dose changes in a combination of ERP and behavioral variables, this study represents a new approach in the search for clinically useful predictors of response to stimulants in ADHD.
We hypothesized that ERPs and behavioral variables that have previously been found to differ in children with ADHD compared with healthy controls would also be affected by a dose of stimulant medication, reflecting an improvement towards normalization. We hypothesized that these effects would be specific to the REs, and that the non-REs would show smaller effects, thus making the magnitude of single dose effects predictive of later classification.
The differential single dose effects in REs vs. non-REs on most of the investigated variables have not been investigated before. The study was therefore partly exploratory in nature, and the predictive power of the different variables was investigated individually before variables found to be significantly different in REs and nonREs were entered into a hierarchical logistic regression analysis. To avoid model over fitting, the first block of the logistic regression analysis only contained the two variables that most strongly differentiated REs from non-REs and background variables differing significantly between the groups.
To compare the results with prediction based on baseline data, regression was also performed on results from the baseline test. We hypothesized that a model based on single-dose effects would result in higher accuracy of prediction than would prediction based on baseline data.
Methods

Participants and diagnostic procedures
A neuropsychiatric team comprising two neuropsychologists, a pediatrician, and a specialist in school psychology, all with several decades of clinical experience, diagnosed 87 patients with ADHD in accordance with DSM-IV. Patients with IQs below 70 or diagnosed brain injury were excluded. Common comorbidities, like behavioral and emotional disorders, learning disabilities, or autism spectrum disorders were included. Diagnoses were based on medical history, clinical interviews [DAWBA (Goodman et al., 2000) or Kiddie-SADS (Kaufman et al., 2009) ], rating scales from parents, teachers and patients over 12 years, observations and school reports. One or more of the following scales were applied: Conners' rating scale revised/Conners3 (Conners, 2008) , Behavior Rating Inventory of Executive Function (BRIEF; Gioia and Isquith, 2000) , the Five to Fifteen questionnaire (FTF -5-15, Lambek and Trillingsgaard, 2015) . School reports described academic and psychosocial functioning.
After a diagnosis of ADHD was established, the patients and their parents were informed about and offered participation in the study, which consisted of two ERP registrations, once without and once on a single dose of stimulant medication, followed by a four-week medication trial. A flow chart illustrating the timing of the different procedures is shown in Fig. 1 . The Regional Committee for Medical Research Ethics approved the project. Eleven cases were excluded because of the technical quality of the recordings and one case for non-compliance.
Assessment of ERPs
EEG was recorded using a Mitsar 201 19-channel EEG system (http://www.mitsar-medical.com) during a 20-min cued go/no-go task. The task consisted of 400 pairs of images presented for 100 ms, with 1100-ms inter-stimulus intervals between the onset of the cue and the onset of the imperative stimulus, and 3000-ms inter-trial intervals. Participants were instructed to press the left mouse button as quickly as possible, but only when the two paired images were animals (A-A: go)-not ''animal-plant" (A-P: no-go), ''plant-human," or ''plant-plant" (100 pairs in each category). Correct responses had to occur within 200-1000 ms after presentation of the imperative stimulus. Failure to respond to A-A pairs within this time interval was considered omission errors, and responses within this time interval for A-P pairs were considered commission errors.
Input signals were referenced to earlobe electrodes, filtered between 0.5 Hz and 50 Hz, and digitized at a sampling rate of 250 Hz, with impedance kept below 5 kX for all 19 electrodes. An electrode cap with tin electrodes (Electro-cap International, Eaton OH, USA) was applied with electrodes placed in accordance with the international 10-20 system at sites Fz, Cz, Pz, Fp1/2, F3/4, F7/8, T3/4, T5/6, C3/4, P3/4, and O1/2. The EEG data were re-referenced offline to the common average montage prior to data processing, and eye blink artifacts were corrected by zeroing the activation curves of individual independent components corresponding to eye blinks (Jung et al., 2000; Vigario, 1997) . Epochs of the filtered EEG with excessive amplitude (100 lV) and/or excessively fast (35 lV in 20-35 Hz band) and slow (50 lV in 0-1 Hz band) frequency activities were automatically marked and excluded from analysis.
ERPs were registered twice-first without medication (test 1; T1) and later with a single dose of MPH (N = 79) or DEX (N = 8) (test 2; T2). As the study was conducted in a natural clinical setting, there was substantial variation in the time interval between the two tests (1-45 weeks), although the majority of participants completed T2 within 12 weeks from T1. The reasons for some participants having particularly long time intervals between tests, was that T2 was always conducted at the onset of the participant's clinical medication try out, whereas T1 was conducted at the point in time when the participant was first offered a try out of stimulant medication. The reasons for postponement of the try out were mixed; change of school, moving to a new district, a wish to postpone the medication trial from late spring till autumn, parents needing time to consider the medication offer etc. Using ChiSquare, we compared the distribution of REs and non-REs in participants completing T2 within 12 weeks after T1 (N = 65) with those (N = 22) completing T2 more than 12 weeks after T1.
ERPs were computed by averaging the remaining trials after correction and rejection of artifacts. For REs in T1, the mean number of correct trials after artifact rejection was 151 (SD = 34) in the cue-condition (all trials with A as the first stimulus), 66 (SD = 23) in the go condition, and 66 (SD = 18) in the no-go condition. For the non-REs, the mean number of trials was 159 (SD = 35) in the cue-condition, 74 (SD = 18) in the go, and 75 (SD = 21) in the nogo condition.
For REs in T2, the mean number of correct trials after artifact rejection was 166 (SD = 33) in the cue-condition, 77 (SD = 16) in the go condition, and 82 (SD = 18) in the no-go condition. For the non-REs, the mean number of trials was 156 (SD = 40) in the The amplitudes were measured at the midline electrodes where the component was observed to be present in the grand mean ERPs of the groups. The component amplitudes were measured at the following electrodes and within the following time intervals: ERPs after stimulus 1; cue-P3, at Pz (270 ms -370 ms); CNV at Fz, Cz, Pz (1000 ms-1100 ms). ERPs after stimulus 2: P3go at Pz (260 ms-400 ms); N2no-go at Fz and Cz (220 ms-330 ms); P3no-go at Fz, Cz, Pz (300 ms-500 ms). The CNV component, which is a slow fluctuation with largest amplitude immediately preceding the imperative stimulus, was measured automatically as the mean amplitude the last 100 ms before presentation of the second stimulus in the cue condition. All other component amplitudes were measured manually as the local peak amplitude within a pre-defined time interval based on the onset and offset of the component in the grand mean ERP waveform collapsed across groups (RE/non-RE) and tests (T1/T2). The local peak amplitude refers to the point within the defined time window for the component of interest with the largest amplitude which is surrounded on both sides by lower voltages, thereby avoiding measuring the offset of preceding or onset of following components (Luck, 2014) . As the WinEEG software does not contain an algorithm for automatically exporting local peak amplitudes, ERP component amplitudes were measured manually by two of the authors (JFB and IEA), blinded to RE vs. non-RE classification.
Medication procedure and criteria for classification of response
The participants had all been diagnosed with ADHD, and were offered a systematic trial on stimulant medication lasting at least 4 weeks. Both ERP registrations (T1 and T2) were completed before the 4-week trial, and took place in the same office at approximately the same time of day. For the single dose test, 54 participants received 10 mg MPH, 25 received 15 mg MPH, and 8 participants received 7.5 mg DEX. Those who received 15 mg MPH were 14 years or older, without comorbid anxiety disorders and were not small for their age. Those who received DEX had experienced side-effects or made no clinical gains on previous MPH trials.
The standard procedure for the 4-week trial was single tablets of MPH, titrated from 5 mg Â 1 per day, up to 20 mg Â 3 per day. Doses were not increased to maximum if side-effects occurred for more than one or two days, or if clinical effects were clearly seen on lower doses. Daily ratings of ADHD symptoms were completed by parents and teachers before onset of the trial period and during the 4 weeks. They were all informed that these ratings were performed to evaluate effects of the medication try out. Teachers were not informed about doses or titration. Children over 9 years of age were encouraged to complete daily self-ratings. Some of the parents and teachers completed daily 4-point ratings of the 18 ADHD symptoms in the DSM-IV. In other cases, abbreviated forms asking for comparisons with the period before onset of medication (better, as usual, or worse) were used. Similarly, the children were asked to evaluate their attention, behavior, and feelings, as better, worse, or the same, compared with the period before onset of medication. Daily ratings were used to capture more of the variation of functioning than weekly ratings do. In most cases, parents and children completed a side-effects questionnaire together once a week, the first time before onset of the medication trial. The parents were invited to contact the clinic with any questions they might have during this period.
At the end of the 4-week try out, meetings with parents, teachers, and patients over the age of 12 were arranged. The participants were asked to tell us about the 4-week period. Had they experienced positive or negative changes? What were the effects of increasing doses? Did anything change? They were also asked to describe any side-effects. A previous paper (Ogrim et al., 2014) describes the reported positive effects.
All important information, from scales, tests, meetings and phone calls, was registered in the patients' medical records. The first author and a team psychologist not involved in the research independently evaluated this information, which did not include ERPs or other data from the cued go/no-go task. The following scores regarding clinical effects were assigned. Score 1 (RE): Positive changes in core ADHD symptoms reported from at least two informants (parent, teacher, self) and a joint decision to continue medication. Score 0 (non-RE): Significant clinical changes in core symptoms were not seen, or negative effects on these symptoms were reported. Medication with MPH or DEX was discontinued, sometimes after a few weeks of prolonged trial. The cases falling in between these two scores were classified to the score that overall best described the available information. Inter-rater agreement was 80% before consensus discussions. The cases where the raters differed in classifications were primarily cases where parents and teachers differed in their opinions, and cases with only modest gains.
Variables in the model
The two groups were compared for changes in behavioral variables in the cued go/no-go task (omission errors, commission errors, RT, and RTvar), and amplitudes of the ERP components cue-P3, CNV, P3go, N2no-go, and P3no-go. To control for background and possible confounding variables differing between REs and non-REs, the groups were also compared in terms of age, gender, time between the two tests (<12 weeks vs. >12 weeks), subtypes of ADHD, the presence of comorbid disorders, and IQ. Background or confounding variables that significantly differed between REs and non-REs were controlled for in the logistic regression analysis.
Statistical methods
To check the group differences in possible confounding variables, Chi-Squares were applied for dichotomous variables and independent-samples t-tests for continuous variables.
To identify behavioral variables and ERP components associated with clinical outcomes, we compared the effects of a single dose of MPH or DEX with the same variables as measured without medication by subtracting the two values (T2-T1). These difference scores were compared in REs vs. non-REs using independent samples ttests for behavioral data. For the ERP component amplitudes, these differences were assessed using multivariate analyses of variances (MANOVA). The MANOVAs included electrode site and medication (T1 vs. T2) as within-subjects factors, and group (RE vs. non-RE) as a between-subjects factor. We performed multivariate analyses rather than traditional repeated-measures ANOVA, as the multivariate model does not assume sphericity-an assumption often violated by psychophysiological data (Picton et al., 2000) . Posthoc analyses were conducted using the Bonferroni correction. Corrected p-values are reported.
Variables that were differentially affected by stimulant medication in REs and non-REs were included in a hierarchical logistic regression analysis. To reduce the risk of bias (Peduzzi et al., 1996) , only the two ERP or behavioral variables showing the largest effect sizes in differentiating medication effects in REs and non-REs were included in the first step. Background variables that differed significantly between the groups were also included in the first step to control for the possibly confounding effects of these variables. In the second step, the remaining ERP and behavioral variables that were significantly different in REs and non-REs were included to investigate if significant gains could be achieved by including these variables. To compare predictions based on singledose changes with predictions based on results for REs and nonREs at baseline, we also performed a regression analysis using the data from the baseline ERP registration only.
Statistical analyses were performed using SPSS Vol. 21 (http:// www.spss.com) and STATA 14.1 (http://stata.com), with alpha level set at .05. Cohen's d effect sizes were calculated with correction for different sample sizes.
Results
As shown in Table 1 , neither time interval between tests (<12 weeks vs. >12 weeks) nor type of medication (MPH vs. DEX) differed significantly between REs and non-REs. No significant between-groups differences were found for subtype of ADHD, comorbid disorders, or gender. The mean age in the REs was 1.2 years younger than in the non-REs (p = .04). Age was therefore controlled for in the regression analysis. The non-RE group scored a mean of 8 IQ points lower than REs (p = .03). IQ data were unavailable for 13 patients, however, and was therefore not controlled for in the regression analysis. Table 2 outlines the descriptive statistics and summary of the MANOVA interaction effects involving group and medication effects on ERP component amplitudes. There were no significant group differences in effects of stimulant medication on the N2no-go or P3go.
A significant group by medication interaction for the cue-P3 was found (p < .001 d = 0.90). The effect of a single dose of medication resulted in no significant change in the REs (mean difference = 0.53 lV, p = .134), but a significant decrease in amplitude in the non-REs (mean difference = À1.48 lV, p = .006). A significant three-way interaction was found for the CNV, with the effect of a single dose of medication differing significantly between groups only at Cz (p = .004, d = 0.79): Non-REs demonstrated a significant decrease in CNV amplitude on a single dose of medication compared with baseline (mean difference = 0.80 lV, p < .018), and REs showed a marginally significant increase (mean difference = À0.51 lV, p = .051).
A significant three-way interaction was found for the P3no-go: The single dose effect was significantly different between groups at both Cz (p < .001, d = 1.76) and Pz (p < .001, d = 1.11), but not at Fz. Pairwise comparisons of the P3no-go amplitude at Cz revealed a significantly larger amplitude on a single dose of medication compared with baseline in REs (mean difference = 4.27 lV, p < .001) and significantly smaller P3no-go amplitudes on a single dose of medication compared with baseline for non-REs (mean difference = À1.80 lV, p = .031). Based on the MANOVA results, changes in cue-P3 amplitude at Pz, and changes in CNV and P3no-go amplitudes at Cz were included in the regression analysis. The grand mean ERPs from the cue, go and no-go conditions at T1 and T2 in the REs and non-REs can be seen in Fig. 2 Table 3 .
Logistic regression analysis
A hierarchical logistic regression analysis was conducted to predict clinical medication response. Of the six ERP or behavioral variables showing differential effects of medication in REs and nonREs, changes in P3no-go amplitude and omission errors showed the largest effect sizes and were included in the first block of the analysis. To control for the age differences between the RE and non-RE groups, age was also included in this step. To investigate whether the addition of other factors would contribute significantly to prediction, the second block of the analysis also included the remaining four variables that individually differed between REs and non-REs.
A test of block 1 against a constant-only model was statistically significant, indicating that the predictor set was more accurate in predicting medication response than a model predicting that all participants would belong to the most prevalent category (REs) (v 2 = 54.55, p < .001, df = 3). Nagelkerke's R 2 of .667 indicated a moderately strong relationship between prediction and grouping. When setting the criterion for classification at .50 (predicting that a participant was an RE if the predicted probability of response was >50%, and a non-RE if <50%), the model had an overall accuracy of 86.2%, correctly classifying 56 of the 62 REs (sensitivity = 90.3%), and 19 of the 25 non-REs (specificity = 76.0%). Prediction of Note: Means and SDs of the ERP component amplitudes at baseline (T1) and on stimulant medication (T2) in the responder and non-responder groups, and tests of significant differences in medication effects (ANOVA) between the groups. Significant differences are marked by ⁄. * p < .05. ** p < .01. *** p < .001. Fig. 2 . Grand mean ERPs from the responders (REs) and non-responders (non-REs) at baseline (T1; gray lines) and on a single-dose of stimulant medication (T2; black lines). The time-intervals within which individual peak amplitudes for the different ERP components were scored are marked by gray boxes. Note: Means and SDs of behavior variables at baseline (T1) and on stimulant medication (T2) in the responder (RE) and non-responder (non-RE) groups, and independent samples t-tests of the differences in medication effects (T2-T1) between the groups. Significant differences are marked by ⁄. *** p < .001.
response was correct in 56 of 62 cases (positive predictive power = 90.3%), and prediction of non-response was correct in 19 of 25 cases (negative predictive power = 76.0%). The Wald criterion demonstrated that only the change in P3no-go amplitude (p < .001) and age (p < .018) contributed significantly to prediction. Fig. 3 shows the increase in the P3no-go component in REs and the decrease in non-REs, as well as the P3no-go amplitudes at T1 and T2 for all individual participants. A summary of the results from block 1 can be found in Table 4 . Block 2, which, in addition to the variables in block 1, also included changes in cue-P3 at Pz, changes in CNV at Cz, changes in RT and changes in RTvar, did not significantly improve the prediction compared with the variables in block 1 only (v 2 = 7.85, p = .097, df = 4). In a clinical setting, one might want to make the classification criterion stricter than .50 to ensure that as few non-REs as possible are wrongly predicted to be REs. Adjusting the classification criterion to .70 for block 1 (predicting that a participant was an RE if the predicted probability was >70%, and a non-RE if <70%), resulted in an overall accuracy of 83.9%, correctly classifying 51 of the 62 REs (sensitivity = 82.3%), and 22 of the 25 non-REs (specificity = 88.0%). Prediction of response was correct in 51 of 54 cases (positive predictive power = 94.4%), and prediction of non-response was correct in 22 of 33 cases (negative predictive power = 66.7%). Although this Fig. 3 . The grand mean P3no-go component at Cz in the responders (REs) and non-responders (non-REs) at baseline (T1; gray lines) and on a single-dose of stimulant medication (T2; black lines). The scatter plot shows the P3no-go amplitudes at T1 and T2 in each individual participant. Note: Summary of results from block 1 in the logistic regression analysis. model with a .70 classification criterion wrongly classifies a few more REs than the .50 cut, the model now only missed 3 participants later classified as non-REs. Fig. 4 illustrates the predicted probability of belonging to the RE group for different changes in P3no-go amplitude at ages 8, 12 and 16. The black and red horizontal lines show the .50 and .70 classification criteria, respectively. Another analysis, not considering age, converted the difference scores (T2-T1) on P3no-go to z-scores and further into quartiles. Patients with a reduction in P3 no-go amplitude of 0.5 mv or more belong to Quartile Group 1 (Q1) with only 25% probability of a positive response. Q4 comprised of patients who increased their P3 no-go amplitude 5.3 mv or more. In this group the probability of being a responder was 100%.
Regression analysis at baseline
At baseline (T1), the REs and non-REs differed significantly only on the P3no-go amplitude (p = .002, d = 0.77), omission errors (p = .004, d = 0.59) and CNV amplitude (p = .033, d = 0.53). Again, the P3no-go amplitude and omission errors were the variables that most strongly differed between REs and non-REs. Again, a hierarchical logistic regression was performed. The first block only contained age, with P3no-go amplitude and omission errors being added in the second block, and CNV amplitude in the third block. The results showed that the second block was significantly better at predicting medication response than the first block alone (v 2 = 13.31, p = .001, df = 2). The third block did not improve prediction significantly (v 2 = 0.07, p = .795, df = 1). In the second block, only P3no-go amplitude contributed significantly to the prediction (p = .014). This T1-model did, however, have lower accuracy of prediction at the .50 classification criterion (75.9%) than the singledose effect model, correctly predicting 56 of the 62 (90.3%) REs, and 10 of the 25 (40.0%) non-REs.
Discussion
A single dose of stimulant medication resulted in a number of differing effects in REs and non-REs in this study. REs had significantly larger reductions in RT, RT variability, and omission errors and larger increases in the amplitudes of the P3no-go and CNV component amplitudes compared with non-REs. Whereas P3no-go and CNV amplitudes increased in REs, significant amplitude reductions were unexpectedly observed in non-REs. Also, whereas the cue-P3 amplitude did not change significantly in the REs, the non-REs demonstrated a significant amplitude reduction on a single dose of medication. These results indicate the effects of stimulant medication are not only absent or reduced in non-REs, but may actually have negative effects in some individuals. Changes in P3no-go amplitude followed by the changes in the number of omissions errors best differentiated REs from non-REs.
The base rate of medication response in the present sample was 71.3%. A logistic regression model using changes in P3no-go amplitude and omission errors as predictors, and controlling for the age of the participants, significantly improved the prediction. When predicting that all participants with a predicted probability of medication response above .50 would be later classified as REs, this model had an overall accuracy of 86.2%. This model correctly identified 90.3% of the REs and 76.0% of the non-REs. When increasing the criterion for predicting that a participant would belong to the RE group to .70 probability of response, the number of non-REs classified correctly increased to 88.0%. Adding the other variables that independently differed between the REs and non-REs did not significantly improve the prediction.
To illustrate the results, Fig. 4 shows the predicted probability of belonging to the RE group for different changes in P3no-go amplitude at ages 8, 12 and 16. The horizontal lines show the .50 and .70 classification criteria, respectively. The choice of where to place the classification criterion will depend on whether one decides that it is of higher importance to identify all non-REs at the cost of also misclassifying some REs, or whether one accepts missing more of the non-REs to avoid misclassifying REs. If the aim of prediction is to monitor potential non-REs to enable quick initiation of alternative treatment options, the .70 criterion will identify most of the non-REs and imply monitoring 38% of the participants. Setting the criterion at .50 would reduce the number of individuals monitored to 29% of the participants, thus saving some resources by not monitoring as many who are later classified as REs, at the cost of missing more of the non-REs. As can be seen from Fig. 4 , the predicted probability of medication response is high in participants with large increments in P3no-go amplitude at all ages, and the confidence intervals are relatively narrow, indicating that the prediction for these individuals can be made with high accuracy. When P3no-go amplitude changes are small or negative, the probability of medication response is lower in older than in younger participants. Also, the confidence intervals increase when changes in P3no-go amplitudes are small or negative, making the estimated probabilities more uncertain.
Only one previous study (Young et al., 1995) has attempted to use ERP changes induced by a single dose of stimulants to predict real-life medication effects: It found an 81% accuracy of prediction using changes in the P3b component amplitude from an auditory oddball task as a predictor variable. Our study did not find significant group differences in stimulant effects on the parietal P3go amplitude; which is an equivalent to the P3b from an oddball task, although the somewhat similar cue-P3 amplitude was significantly reduced on a single dose of medication in the non-REs. The group differences in single dose effects on the more frontally distributed P3no-go component were, however, much larger. This finding is in line with previous functional imaging studies demonstrating that MPH acts primarily by enhancing activation in fronto-striatal areas (Rubia et al., 2014; Czerniak et al., 2013) , areas that have also been indicated as involved in generation of the P3no-go component (see review by Huster et al., 2013) .
Increasing detectability using single-dose administration
Several studies varying in patient selection and treatment response evaluation have attempted to predict response to stimulant medication based on behavioral and/or electrophysiological markers before initiation of medication trials (Hermens et al., 2006; Rubia et al., 2014; Chabot et al., 1999; Ogrim et al., 2014; Johnstone et al., 2013; Czerniak et al., 2013; Linssen et al., 2012 Linssen et al., , 2011 . The easiest, most valid evaluation of improved predictive power as a result of supplementing baseline assessment with assessment on medication is therefore to compare these results with prediction based on baseline assessment, using the same subjects and variables. The variables significantly differentiating REs from non-REs were fewer at baseline (T1) than when investigating the single dose induced changes. Again, P3no-go amplitude and omission errors showed the largest effects. A regression based on P3no-go amplitude and omission errors at baseline (T1), again controlling for the age of the participants, was significantly better than diagnosis alone at predicting later classification. The T1 model did not, however, perform as well as the model using the effects of a single dose of medication as a basis for prediction. In this study, the difference scores used were computed by simply subtracting raw scores at T2 from raw scores at T1, without controlling for group differences at T1. Some variance due to group differences at T1 was thereby maintained in the difference scores, which, in this case, captured more of the differences between the REs and non-REs than baseline scores alone or difference scores controlled for baseline differences. Our results therefore indicate that both baseline differences and the effects of stimulant medication contribute to predicting medication response, and that prediction based on ERP and behavioral data can be improved substantially by making two assessments-baseline and single dose.
Cognitive processes modulated by stimulant medication
The exact cognitive processes reflected in the P3no-go component are still debated. Most studies describe P3no-go as an index of inhibition, despite limited support for this hypothesis (Huster et al., 2013) . Support is stronger for interpreting P3no-go as reflecting a monitoring process. Using independent component analysis, two overlapping and functionally different subcomponents of P3no-go have been identified (Brunner et al., 2015) . There is accumulating evidence that the target-related P3b reflects reactivation of a prepared and well-established stimulus-response link (Verleger et al., 2005 (Verleger et al., , 2015 . In contrast, the P3no-go subcomponent with the shortest latency is thought to reflect activation of an unprepared stimulus-(non-) response link (Aasen and Brunner, 2016) . This activation of a sub-dominant stimulus-response link is slower and requires a higher degree of voluntary control and greater effort (energization) than does implementing prepared actions. The second subcomponent may reflect the proposed monitoring process.
This understanding of P3no-go indicates that the core deficit being improved by stimulant medication in REs may not be inhibition, but rather a problem of initiating appropriate responses requiring effort, and monitoring the quality of ones task performance. In line with this interpretation, the reported benefits of medication were primarily improved sustained attention and initiation of such appropriate behavior as completing homework, rather than inhibition in the form of reduced impulsive acts (Ogrim et al., 2014) . To better understand the specific processes affected by stimulant medication, future studies should investigate possible differential effects of stimulants on the two subcomponents of P3no-go.
Limitations and clinical implications
For our findings to be established as a useful clinical method for predicting stimulant medication response, the results should be replicated in a double-blinded, placebo-controlled, crossover study. As this study was conducted in a naturalistic clinical setting, it has a number of limitations in terms of design. The study did not have a placebo control condition, and neither participants and their parents, nor teachers were blinded as to when the active medication trial was conducted. The participants also knew that they received medication before the second, but not the first ERPregistration, making it possible that placebo or nocebo effects could partly explain the present results, but probably not the differences in REs and non-REs. Also, the clinicians evaluating treatment response knew that the participants had been receiving stimulant medication in the evaluated period. Another limitation is that the time between the baseline and single dose ERP registrations varied a lot, which could increase error variance due to maturational factors. The timing between the two tests did not differ between REs and non-REs, however. Also, some of the observed changes could be due to training rather than single dose effects as the test on a single dose of medication was systematically conducted after the baseline test. This procedure was the same for both groups however.
In addition to these limitations, the inter-rater agreement in terms of medication response was not perfect. Some of the participants wrongly classified by the model could therefore be due to cases where there had been disagreement in the classification based on the four-week try out. This limitation, however, is hard to avoid as there exists no perfect, flawless way of determining what constitutes a ''real" clinical response to stimulant medication. Finally, as the number of studies investigating the effects of stimulant medication on ERP components and behavior are limited, the nature of this study was partially exploratory in nature. The method of first investigating group differences in the different variables and then investigating those with the largest group differences is a method that is more vulnerable to model overfitting than a model purely based on theory and previous findings. A replication of the present study using the variables found to be the most predictive in this study is therefore warranted.
Despite these limitations, the results of this study are highly promising, providing significantly improved prediction compared with prediction based on the base rate of responders in ADHD populations. To avoid long periods of ineffective treatment with stimulants, it is of great importance to identify quickly the non-REs in order to find more effective treatment options for them: another medication and/or psychosocial treatments. Because the mean IQ of non-REs was 8 points lower than those of the REs, non-RE's symptoms may partially reflect inattention and hyperactivity resulting from etiologies other than those of the REs, including factors related to learning disabilities and the posterior attention system (Posner and Petersen, 1990; Petersen and Posner, 2012) .
The data in this study were gathered in a clinic and included patients with the two main subtypes of ADHD, a broad range of comorbidities, and IQs as low as 70, excluding only mental retardation and brain injuries. We believe that our sample resembles the real-world clinical situation and would argue that the results reflect an ecologically valid estimation of predictive power.
